ArticleRheumatology (Oxford, England)2022

Correction to: Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients.

Nathalie Luurssen-Masurel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.